Profil
Peter W.
Letendre served as President, Chief Executive Officer & Director at Pier Pharmaceuticals, Inc. and as a Director at RespireRx Pharmaceuticals, Inc. He was also the Chief Commercial Officer at Replidyne, Inc. from 2005 to 2008.
Letendre received his undergraduate degree in 1980 and his doctorate in 1982 from Massachusetts College of Pharmacy & Health Science.
Ehemalige bekannte Positionen von Peter W. Letendre
| Unternehmen | Position | Ende |
|---|---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Develops and commercializes novel antibiotics to treat infections caused by drug resistant bacteria | Corporate Officer/Principal | 15.04.2008 |
| RESPIRERX PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | - |
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for sleep apnea | Vorstandsvorsitzender | - |
Ausbildung von Peter W. Letendre
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
RespireRx Pharmaceuticals, Inc.
RespireRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates biopharmaceutical company that discovers and develops drug therapies for the treatment of sleep apnea, respiratory depression & other brain-mediated breathing disorders | Health Technology |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Develops and commercializes novel antibiotics to treat infections caused by drug resistant bacteria | Health Technology |
Massachusetts College of Pharmacy & Health Science
Massachusetts College of Pharmacy & Health Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for sleep apnea | Health Technology |
















